Top 3 Ovarian Cancer Molecules : Super PARP Inhibitors
December 23, 2020How Helpful are The Ovarian Cancer Guidelines? [Free Thoughts]
December 24, 20203 Ways to Manage Lynparza/Olaparib-Induced Fatigue Ovarian Cancer
LYNPARZA is the only PARP inhibitor approved for the following 4 types of advanced cancer.
“The goal of cancer treatment is to shrink the tumor and control its growth for as long as possible. This can be accomplished in a variety of ways, such as chemotherapy and targeted therapy, which is a prescription medication that works by targeting the cancer cell’s pathways.”
https://www.lynparza.com/what-is-lynparza.html
Lynparza/Olaparib-Induced Fatigue Ovarian Cancer:
Prior to initiating Olaparib (Lynparza), all patients should be screened for fatigue in order to establish a baseline patient should be well educated that fatigue is one of the most common side effects of a Lynparza.
Fatigue tends to decrease over time. In our experience, fatigue tends to decrease over the first four to six weeks after initiation. Patients should be instructed that dose modifications or dose interruptions may be required in order to keep patients on Olaparib (Lynparza) as long term therapy as clinically indicated.
If your patient’s fatigue increases while on Olaparib (Lynparza) 300 milligrams BID and all other underlying causes have been ruled out and supportive measures have been implemented. You may want to consider holding Olaparib (Lynparza) for a week or longer to let the fatigue return to baseline.
At that point, you may start the drug at the same dose or a reduced dose. The first dose reduction we typically use is 250 milligrams BID. The second dose reduction that we use is 200 milligrams BID.
For patients who have moderate fatigue at baseline. We often start Olaparib (Lynparza) at a lower dose such as 200 milligrams BID. After a period of two to four weeks once the patient acclimates to the drug. You may be able to dose escalate the drug as tolerated.
FAQs about fatigue and olaparib
Q: How can I manage fatigue induced by Lynparza/Olaparib in ovarian cancer?
A: To manage fatigue induced by Lynparza/Olaparib in ovarian cancer, it is important to prioritize rest, engage in light physical activity, maintain a healthy diet, and communicate with your healthcare team about your symptoms.
Q: What are the common symptoms of ovarian cancer that may lead to fatigue?
A: Common symptoms of ovarian cancer that may lead to fatigue include bloating, sleep disturbances, and depressive symptoms. These symptoms can contribute to overall feelings of tiredness and exhaustion.
Q: What are the early signs of ovarian cancer that I should be aware of?
A: Early signs of ovarian cancer may include persistent bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and frequent urination. If you experience these symptoms regularly, it is important to consult your doctor.
Q: How does ovarian cancer-related fatigue impact women with ovarian cancer over time?
A: Ovarian cancer-related fatigue can have a significant impact on the quality of life of women with ovarian cancer over time. It may lead to decreased energy levels, diminished motivation, and challenges in carrying out daily activities.
Q: What are the warning signs of ovarian cancer that should not be ignored?
A: Warning signs of ovarian cancer that should not be ignored include persistent abdominal or pelvic pain, bloating, difficulty eating, feeling full quickly, and changes in bowel habits. If you experience these symptoms, it is important to see your doctor promptly.
Q: How can I effectively manage fatigue in women with ovarian cancer?
A: To effectively manage fatigue in women with ovarian cancer, it is essential to adopt healthy lifestyle practices such as maintaining a balanced diet, staying hydrated, getting regular exercise, and prioritizing adequate rest and sleep.
Q: Why is it crucial for ovarian cancer patients to report their symptoms to their healthcare team?
A: It is crucial for ovarian cancer patients to report their symptoms to their healthcare team because timely communication can help in addressing any potential complications or side effects of treatment, including cancer-related fatigue.